Protective-antigen (PA) based anthrax vaccines confer protection against inhalation anthrax by precluding the establishment of a systemic infection

References

• Hicks CW, Sweeney DA, Cui X, Li Y, Eichacker PQ. An overview of anthrax infection including the recently identified form of disease in injection drug users. Intensive Care Med 2012; 38:1092 - 104; http://dx.doi.org/10.1007/s00134-012-2541-0; PMID: 22527064
   PubMed Web of Science ®Google Scholar
• Mabry R, Brasky K, Geiger R, Carrion R Jr., Hubbard GB, Leppla S, et al. Detection of anthrax toxin in the serum of animals infected with Bacillus anthracis by using engineered immunoassays. Clin Vaccine Immunol 2006; 13:671 - 7; http://dx.doi.org/10.1128/CVI.00023-06; PMID: 16760326
   PubMed Web of Science ®Google Scholar
• IOM Committee to Assess the Safety and Efficacy of the Anthrax Vaccine. The Anthrax Vaccine: Is It Safe? Does It Work? Washington DC: National Academies Press; 2002.
   Google Scholar
• Detailed Safety Review of Anthrax Vaccine adsorbed January 2012, Complied by the Military Vaccine (MILVAX) Agency, US army Medical Command, Falls Church, Virginia http://www.anthrax.osd.mil/documents/854avasafetyrvw.pdf
   Google Scholar
• Wright JG, Quinn CP, Shadomy S, Messonnier N. Use of anthrax vaccine in the United States. Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. MMWR Morb Mortal Wkly Rep 2010; 59:1 - 30; PMID: 20075837
   PubMedGoogle Scholar
• Weiss S, Kobiler D, Levy H, Marcus H, Pass A, Rothschild N, et al. Immunological correlates for protection against intranasal challenge of Bacillus anthracis spores conferred by a protective antigen-based vaccine in rabbits. Infect Immun 2006; 74:394 - 8; http://dx.doi.org/10.1128/IAI.74.1.394-398.2006; PMID: 16368995
   PubMed Web of Science ®Google Scholar
• Chitlaru T, Altboum Z, Reuveny S, Shafferman A. Progress and novel strategies in vaccine development and treatment of anthrax. Immunol Rev 2011; 239:221 - 36; http://dx.doi.org/10.1111/j.1600-065X.2010.00969.x; PMID: 21198675
   PubMed Web of Science ®Google Scholar
• Fay MP, Follmann DA, Lynn F, Schiffer JM, Stark GV, Kohberger R, et al. Anthrax vaccine-induced antibodies provide cross-species prediction of survival to aerosol challenge. Sci Transl Med 2012; 4:ra126; http://dx.doi.org/10.1126/scitranslmed.3004073; PMID: 22972844
   PubMed Web of Science ®Google Scholar
• Merkel TJ, Perera PY, Kelly VK, Verma A, Llewellyn ZN, Waldmann TA, et al. Development of a highly efficacious vaccinia-based dual vaccine against smallpox and anthrax, two important bioterror entities. Proc Natl Acad Sci U S A 2010; 107:18091 - 6; http://dx.doi.org/10.1073/pnas.1013083107; PMID: 20921397
   PubMed Web of Science ®Google Scholar
• Comer JE, Ray BD, Henning LN, Stark GV, Barnewall RE, Mott JM, et al. Characterization of a therapeutic model of inhalational anthrax using an increase in body temperature in New Zealand white rabbits as a trigger for treatment. Clin Vaccine Immunol 2012; 19:1517 - 25; http://dx.doi.org/10.1128/CVI.00292-12; PMID: 22837095
   PubMed Web of Science ®Google Scholar
• Kuklenyik Z, Boyer AE, Lins R, Quinn CP, Gallegos-Candela M, Woolfitt A, et al. Comparison of MALDI-TOF-MS and HPLC-ESI-MS/MS for endopeptidase activity-based quantification of Anthrax lethal factor in serum. Anal Chem 2011; 83:1760 - 5; http://dx.doi.org/10.1021/ac1030144; PMID: 21302970
   PubMed Web of Science ®Google Scholar
• Molin FD, Fasanella A, Simonato M, Garofolo G, Montecucco C, Tonello F. Ratio of lethal and edema factors in rabbit systemic anthrax. Toxicon 2008; 52:824 - 8; http://dx.doi.org/10.1016/j.toxicon.2008.08.011; PMID: 18812184
   PubMed Web of Science ®Google Scholar
• Lee JS, Hadjipanayis AG, Welkos SL. Venezuelan equine encephalitis virus-vectored vaccines protect mice against anthrax spore challenge. Infect Immun 2003; 71:1491 - 6; http://dx.doi.org/10.1128/IAI.71.3.1491-1496.2003; PMID: 12595467
   PubMed Web of Science ®Google Scholar
• McConnell MJ, Hanna PC, Imperiale MJ. Cytokine response and survival of mice immunized with an adenovirus expressing Bacillus anthracis protective antigen domain 4. Infect Immun 2006; 74:1009 - 15; http://dx.doi.org/10.1128/IAI.74.2.1009-1015.2006; PMID: 16428747
   PubMed Web of Science ®Google Scholar
• Keitel WA, Treanor JJ, El Sahly HM, Evans TG, Kopper S, Whitlow V, et al. Evaluation of a plasmid DNA-based anthrax vaccine in rabbits, nonhuman primates and healthy adults. Hum Vaccin 2009; 5:536 - 44; http://dx.doi.org/10.4161/hv.5.8.8725; PMID: 19458488
   PubMed Web of Science ®Google Scholar
• Stepanov AV, Marinin LI, Pomerantsev AP, Staritsin NA. Development of novel vaccines against anthrax in man. J Biotechnol 1996; 44:155 - 60; http://dx.doi.org/10.1016/0168-1656(95)00092-5; PMID: 8717399
   PubMed Web of Science ®Google Scholar
• Welkos S, Little S, Friedlander A, Fritz D, Fellows P. The role of antibodies to Bacillus anthracis and anthrax toxin components in inhibiting the early stages of infection by anthrax spores. Microbiology 2001; 147:1677 - 85; PMID: 11390699
   PubMed Web of Science ®Google Scholar
• Loving CL, Khurana T, Osorio M, Lee GM, Kelly VK, Stibitz S, et al. Role of anthrax toxins in dissemination, disease progression, and induction of protective adaptive immunity in the mouse aerosol challenge model. Infect Immun 2009; 77:255 - 65; http://dx.doi.org/10.1128/IAI.00633-08; PMID: 18955474
   PubMed Web of Science ®Google Scholar
• Weiner ZP, Glomski IJ. Updating perspectives on the initiation of Bacillus anthracis growth and dissemination through its host. Infect Immun 2012; 80:1626 - 33; http://dx.doi.org/10.1128/IAI.06061-11; PMID: 22354031
   PubMed Web of Science ®Google Scholar
• Plaut RD, Kelly VK, Lee GM, Stibitz S, Merkel TJ. Dissemination bottleneck in a murine model of inhalational anthrax. Infect Immun 2012; 80:3189 - 93; http://dx.doi.org/10.1128/IAI.00515-12; PMID: 22753373
   PubMed Web of Science ®Google Scholar
• Peterson JW, Comer JE, Baze WB, Noffsinger DM, Wenglikowski A, Walberg KG, et al. Human monoclonal antibody AVP-21D9 to protective antigen reduces dissemination of the Bacillus anthracis Ames strain from the lungs in a rabbit model. Infect Immun 2007; 75:3414 - 24; http://dx.doi.org/10.1128/IAI.00352-07; PMID: 17452469
   PubMed Web of Science ®Google Scholar
• Pitt MLM, Ivins BE, Estep JE, Farchaus J, Friedlander AM. Comparison of the efficacy of purified protective antigen and MDPH to protect non-human primates from inhalation anthrax. Salisbury Med Bull Suppl 1996; 87:130
   Google Scholar
• Human Genome Sciences Inc. Anti-Infectives Advisory Committee Briefing Document: Raxibacumab, Treatment of Inhalation Anthrax, BLA 125349, September 21, 2009 (Food and Drug Administration, Silver Spring, MD, 2009).
   Google Scholar
• Luxembourg A, Hannaman D, Nolan E, Ellefsen B, Nakamura G, Chau L, et al. Potentiation of an anthrax DNA vaccine with electroporation. Vaccine 2008; 26:5216 - 22; http://dx.doi.org/10.1016/j.vaccine.2008.03.064; PMID: 18462850
   PubMed Web of Science ®Google Scholar
• Livingston BD, Little SF, Luxembourg A, Ellefsen B, Hannaman D. Comparative performance of a licensed anthrax vaccine versus electroporation based delivery of a PA encoding DNA vaccine in rhesus macaques. Vaccine 2010; 28:1056 - 61; http://dx.doi.org/10.1016/j.vaccine.2009.10.111; PMID: 19896452
   PubMed Web of Science ®Google Scholar
• Li H, Soroka SD, Taylor TH Jr., Stamey KL, Stinson KW, Freeman AE, et al. Standardized, mathematical model-based and validated in vitro analysis of anthrax lethal toxin neutralization. J Immunol Methods 2008; 333:89 - 106; http://dx.doi.org/10.1016/j.jim.2008.01.007; PMID: 18304568
   PubMed Web of Science ®Google Scholar